Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://dspace.nuph.edu.ua/handle/123456789/14325
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorTolochko, V. M.-
dc.contributor.authorAdonkina, V. Iu.-
dc.contributor.authorSemchenko, K. V.-
dc.contributor.authorТолочко, В. М.-
dc.contributor.authorАдонкина, В. Ю.-
dc.contributor.authorАдонкіна, В. Ю.-
dc.contributor.authorСемченко, К. В.-
dc.date.accessioned2018-02-02T10:36:21Z-
dc.date.available2018-02-02T10:36:21Z-
dc.date.issued2017-
dc.identifier.citationTolochko, V. M. Research of economic accessibility and costs optimization of chemotherapy treatment schemes of patients with breast cancer in Ukraine / V. M. Tolochko, V. Iu. Adonkina, K. V. Semchenko // The Pharma Innovation Journal. – 2017. – № 6 (12). – Р. 253-257.en_US
dc.identifier.urihttp://dspace.nuph.edu.ua/handle/123456789/14325-
dc.description.abstractBreast cancer is ranked first in the cancer-related morbidity and mortality rate of malignant neoplasms of the female population around the world. In recent years, approaches to cancer treatment have changed, chemotherapy has become one of the essential component of a comprehensive treatment that is long-lasting and high-value. Considering the high cost of chemotherapeutic treatment schemes and low solvency of the population of the country, it is advisable to conduct a study on the economic availability of chemotherapy schemes for breast cancer patients’ treatment and optimizing their costs by minimizing costs in order to offer the most cost-effective therapies. During the analysis, it was found that the replacement of high-cost medicines in the CMF chemotherapeutic schemes with medicines with the lowest cost of the course dose, which were selected on the basis of the cost-minimization analysis, provides cost savings of $ 48.21 per patient, which allows additional treatment for more patients. The results of the assessment of the socioeconomic availability of chemotherapeutic treatment schemes showed that almost all schemes are poorly available to the Ukrainian patient. Only two schemes: CMF and AC, which have an adequate solvency ratio of 12.12% and 14.8%, are moderately available.en_US
dc.language.isoenen_US
dc.subjectbreast canceren_US
dc.subjectadequacy of solvencyen_US
dc.subjecteconomic availabilityen_US
dc.subjectcost minimizationen_US
dc.subjecttreatment schemesen_US
dc.subjectmalignant neoplasmsen_US
dc.titleResearch of economic accessibility and costs optimization of chemotherapy treatment schemes of patients with breast cancer in Ukraineen_US
dc.typeArticleen_US
Розташовується у зібраннях:Наукові публікації В. М. Толочко
Наукові публікації кафедри АТЛ
Наукові публікації кафедри організації,економіки та управління фармацією ІПКСФ

Файли цього матеріалу:
Файл Опис РозмірФормат 
Research of economic accessibility.pdf257,07 kBAdobe PDFПереглянути/відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.